A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRATM) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer.

  • Ahern, Elizabeth (Primary Chief Investigator (PCI))
  • Frentzas, Sophia (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description


StatusActive
Effective start/end date27/04/21 → 26/04/26

Keywords

  • clinical trial
  • phase 1 and 2 study
  • treatment efficacy
  • treatment safety
  • Metastatic Cancer